Dimitrios Sagris

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Scott E. Kasner, Balakumar Swaminathan, Pablo M. Lavados et al. · The Lancet Neurology · 2018 · 177 citations · Full text

Global Impact of COVID-19 on Stroke Care and IV Thrombolysis

Raul G. Nogueira, Muhammad M. Qureshi, Mohamad Abdalkader et al. · Neurology · 2021 · 151 citations · Full text

Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study

Maurizio Paciaroni, Valeria Caso, Giancarlo Agnelli et al. · Stroke · 2022 · 70 citations · Full text

Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society

Dimitrios Sagris, George Ntaios, Georgios Georgiopoulos et al. · International Journal of Stroke · 2020 · 18 citations

Lipid Modification, Thrombosis, Lipid Disorder +15

Validation of the AF-ESUS score to identify patients with embolic stroke of undetermined source and low risk of device-detected atrial fibrillation

Alkisti Kitsiou, Dimitrios Sagris, Wolf‐Rüdiger Schäbitz et al. · European Journal of Internal Medicine · 2021 · 17 citations

Cerebrovascular Disease, Thrombosis, Electrophysiological Evaluation +17